Endoxifen Usage in Bipolar Disorders Patients: My Experiential Journey

Downloads

Published

2024-06-03

DOI:

https://doi.org/10.54169/ijocp.v4i01.113

Dimensions Badge

Issue

Vol. 4 No. 01 (2024): Indian Journal of Clinical Psychiatry

Section

OPINION

License

Copyright (c) 2024 Prasad R Gundugurti, Shivangini Singh, Simhachalam Gurugubelli, Sri R Vemulakonda

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Authors

  • Prasad R Gundugurti Department of Schizophrenia and Psychopharmacology, Asha Hospital, Hyderabad, Telangana, India.
  • Shivangini Singh Department of Psychiatry, King George Medical College, Lucknow, Uttar Pradesh, India.
  • Simhachalam Gurugubelli Mississippi, United States of America
  • Sri R Vemulakonda Senior Research Officer, Chicago, Illinois

Abstract

Bipolar affective disorder is a severe mental illness that affects 0.3% of the Indian population, as estimated in the National Mental Health Survey 2016.1 Antipsychotic drugs and mood stabilizers have both been used as first-line agents in the treatment of the manic phase of bipolar I disorder, either singly or in combination. Tamoxifen, a protein kinase C (PKC) inhibitor, has shown efficacy in the treatment of the manic phase of bipolar I disorder. Tamoxifen is recommended as a third-line agent in the treatment of bipolar mania, as per CANMAT and ISBD 2019 treatment guidelines on bipolar disorder.2

How to Cite

Gundugurti, P. R., Singh, S., Gurugubelli, S., & Vemulakonda, S. R. (2024). Endoxifen Usage in Bipolar Disorders Patients: My Experiential Journey. Indian Journal of Clinical Psychiatry, 4(01), 14–16. https://doi.org/10.54169/ijocp.v4i01.113

Downloads

Download data is not yet available.